Broad genomic sequencing extends survival in advanced lung cancer patients
New research in the November 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that patients with advanced non-small cell lung cancer (NSCLC) lived longer when they received broad-based genomic sequencing (BGS)-testing a large panel of dozens or hundreds of genes at once-before starting treatment, compared with patients who received more limited biomarker testing of just one or two genes.
13 Nov 08:29 · News-Medical